DBV Technologies S.A. American Depositary Shares DBVT

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

DBVT hizo una agrupación de acciones (split inverso) de 1:5 el 29 de noviembre de 2024: cada 5 acciones se juntaron en una. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

• GlobeNewswire Inc. 29 sept

  DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years

  DBV Technologies submitted a Biologics License Application (BLA) to the FDA for VIASKIN® Peanut Patch, a non-invasive epicutaneous immunotherapy treatment for peanut allergies in children aged 4-7 years. The submission is supported by positive results from the VITESSE Phase 3 clinical trial involving 654 children, the largest immunotherapy trial for this population. DBV has requested Priority Review status.

  

• GlobeNewswire Inc. 29 sept

  DBV Technologies annonce le dépôt de sa demande de licence biologique (BLA) auprès de la Food and Drug Administration des Etats-Unis pour le patch VIASKIN® Peanut destiné aux enfants âgés de 4 à 7 ans.

  DBV Technologies announced the submission of a Biologics License Application (BLA) to the FDA for its VIASKIN® Peanut patch, designed to treat peanut allergies in children aged 4-7 years. The application is based on positive results from the Phase 3 VITESSE clinical trial, the largest immunotherapy study conducted in this patient population, involving 654 children. DBV has requested priority review of the BLA.

  

• GlobeNewswire Inc. 2 sept

  Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 août 2026

  DBV Technologies announced the sale of approximately $50 million of American Depositary Shares (ADSs) through its At-The-Market (ATM) program on Nasdaq. The company had previously filed an ATM prospectus for up to $150 million in sales.

  

• GlobeNewswire Inc. 2 sept

  Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026

  DBV Technologies announced the sale of approximately $50 million of American Depositary Shares (ADSs) through its At-The-Market (ATM) program on Nasdaq. The company had previously filed an ATM prospectus for up to $150 million in sales. As of August 31, 2026, the company had 314,388,807 total shares outstanding.

  

• GlobeNewswire Inc. 30 jul

  DBV Technologies annonce le placement d’ADS pour un montant d’environ 50 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq

  DBV Technologies announced the placement of approximately $50 million in American Depositary Shares (ADS) with RA Capital Management through its At-The-Market (ATM) program on Nasdaq. The company will issue 18.288 million new ordinary shares at $13.67 per ADS, representing a 5.82% dilution to existing shareholders. The transaction is expected to close on August 3, 2026.